Kornimate/medical-research-clean huggingface dataset:
episodic future thinking and future thinking priming for smoking cessation

Conditions: Tobacco-Related Carcinoma

Summary: this trial studies the main and interactive effects of episodic future thinking and future thinking priming tasks on helping participants to quit smoking. episodic future thinking and future thinking priming tasks may decrease delay discounting rates and reduce relapse to smoking and help participants quit smoking.

primary objective: i. to quantify the main and interactive effects of the episodic future thinking (eft) and future thinking priming (ftp) tasks on delay discounting rate, latency to relapse, and multiple abstinence and self-regulation measures among smokers (n=76) who call a busy quitline to quit smoking. outline: participants are randomized to 1 of 4 arms. arm i: participants are provided with forever free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. participants also receive 1 proactive coaching call within 24 hours of quit date. beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks. arm ii: participants are provided with forever free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. participants also receive 1 proactive coaching call within 24 hours of quit date. beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks. arm iii: participants are provided with forever free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. participants also receive 1 proactive coaching call within 24 hours of quit date. beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks. arm iv: participants are provided with forever free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. participants also receive 1 proactive coaching call within 24 hours of quit date. beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.

Eligibility criteria:
inclusion criteria: * smoke \>= 8 cigarettes daily * planning to quit in the next 14 days * no regular use of other tobacco products * access to the internet * in possession of a smartphone with text messaging capabilities * in possession of an email address accessible at least every other day exclusion criteria: * unable or unwilling to provide consent * unable to provide data to the research team after the quit date * current use of bupropion or varenicline * drinking \>= 20 alcoholic drinks per week * use of drugs of abuse in the past 30 days * living in the same household as a participant already enrolled in this study
novel ecco2r device for hypercapnic respiratory failure

Conditions: Hypercapnic Respiratory Failure

Summary: the objective of this study is to assess the efficacy and safety of this new prismalung+ membrane in its intended clinical setting by demonstrating a reduction in ventilatory parameters and pulmonary energy load or the successful maintenance of spontaneous breathing, respectively, the absence of the need to initiate vv-ecmo therapy, and initial survival.

our hypotheses are that decarboxylation therapy by means of the novel prismalung+ membrane in patients with hypercapnic respiratory failure (i) allows the reduction of tidal volume, peak airway pressure, dp and pulmonary energy load (as measured by auc over 72 hours) as compared to baseline in mechanically ventilated patients or is associated with successful continuation of spontaneous breathing despite respiratory exhaustion (no decision to intubate), and that these patients (ii) warrant no decision to initiate vv-ecmo therapy and (iii) do not experience early mortality. the primary objectives of the study are to test our hypotheses i to iii by applying the novel prismalung+ ecco2r device in mechanically ventilated patients and spontaneously breathing patients experiencing hypercapnic respiratory failure in a multi-central prospective trial in three experienced intensive care units in switzerland.

Eligibility criteria:
inclusion criteria: * mechanically ventilated patient: (i) progressive respiratory failure (ph≤7.25 and/ or paco2 ≥9 kpa) during mechanical ventilation (ii) with an inability to maintain lung protective ventilation (vt\<4 ml/kg, ppeak \<30 mbar, driving pressure ≤12 mbar) * or awake spontaneously breathing patient: respiratory exhaustion (ph≤7.25 and/or paco2 ≥9 kpa) * and informed consent as documented by signature exclusion criteria: * mechanical ventilation group: need for v-v ecmo * awake spontaneously breathing group: need for mechanical ventilation due to inability to remain un-sedated * thrombocytopenia (\<100g/l) * contraindications for heparin therapy (history of heparin antibodies, previous history of intracranial bleeding) * patients under 18 years of age * women who are pregnant or breast feeding * previous enrolment into the current study * enrolment of the investigator, his/her family members, employees and other dependent persons
infusion of t-regulatory cells in kidney transplant recipients (the one study)

Conditions: Kidney Failure, Kidney Transplant

Summary: this research study is for patients who are going to receive a kidney transplant from a living donor. after kidney transplantation, it is necessary for transplant recipients to take "immunosuppressive drugs". these drugs work by preventing the body's immune cells from attacking and "rejecting" the new kidney. taking these drugs long-term may also cause harm to the transplanted kidney. therefore, the transplant community is very interested in finding ways to decrease immunosuppressive drug treatment and further reduce the risk of kidney rejection. one method to do so is known as "induction of tolerance", which is when the person who receives a transplant has treatment to make their immune cells tolerant to the donor cells. in this study, we will try to induce tolerance by mixing recipient cells and their donor's cells together with belatacept, an immunosuppressive drug. belatacept is a protein that attaches to immune system cells, interferes with the immune response and results in tolerance induction. after we mix the recipient cells with the donor's cells, we will sort out one particular kind of immune cell, called a regulatory t cell, and inject them back into the recipient. regulatory t cells are the cells that are affected by induction to reduce rejection of donated organs. this method for inducing tolerance has been used in bone marrow transplantation, but this is the first time it is being done in kidney transplantation. this study is being conducted as part of a unique collaboration of us and eu centers called the one study. the one study centers have agreed to work together using common protocols and procedures but with each testing their own regulatory population for safety and the ability to promote kidney survival. sharing data among the participating sites will permit a deeper understanding of how and why some treatments might succeed while others work less well.


Eligibility criteria:
key recipient inclusion criteria: * chronic renal insufficiency necessitating kidney transplantation * aged at least 18 years * donor is abo (blood type) compatible key recipient exclusion criteria: * hiv positive, ebv negative, or suffering from chronic viral hepatitis or tuberculosis * previously received any tissue or organ transplant other than planned kidney graft * genetically identical to the prospective organ donor at the hla loci (0-0-0 mismatch) * panel reactive antibodies (pra) \>20% * concomitant malignancy or history of malignancy within 5 years prior to planned study entry (excluding successfully-treated non metastatic basal/squamous cell carcinoma of the skin) * ongoing treatment with systemic immunosuppressive drugs at study entry
the alabama nsaids patient safety survey, phase ii: reducing disparities in risk awareness and communication

Conditions: Pain Management

Summary: the investigators propose a two-year group randomized trial of physician practices to test the effectiveness of an interactive dvd that presents a culturally appropriate communication training program for patients called "how to talk to your doctor (and get your doctor to talk to you!)" in promoting safe prescription and use of nonsteroidal anti-inflammatory drugs (nsaids) in the outpatient setting (htttyd-nsaids). the outcome of interest is safer use of nsaids as reported by patients. the aims are to: aim 1. develop an interactive dvd (how to talk to your doctor about nsaids, htttyd-nsaids) that presents culturally appropriate "stories" through which a viewer can learn risk factors for adverse effects related to nsaids; and communication behaviors for talking about nsaids with their doctor. aim 2. conduct a group-randomized trial to test the following three hypotheses about the effectiveness of the interactive dvd in promoting safer use of nsaids: hypothesis 1: intervention group patients will be more likely to report that they had a conversation with their doctor about safe nsaid use than control group patients. hypothesis 2: intervention patients will report significantly fewer risky nsaid ingestion behaviors (e.g., concomitant use of otc and prescription nsaids) than control patients. hypothesis 3: there will be no difference in the intervention's effectiveness between african american and white participants.

nonsteroidal anti-inflammatory drugs (nsaids), expose patients to substantial risk of toxicity. risks are compounded by the fact that patients may frequently take both over-the-counter (otc) and prescription nsaids, a fact they often do not report to their physician. further, our prior work suggests that african american patients may be at greater risk from nsaids than whites. while the consequences of unsafe nsaid use are well recognized, effective ways of improving safe use are as yet poorly established. three findings from medical interaction research suggest that a solution may lie in improving doctor-patient communication. first, patients' communicative behaviors influence those of their doctors. patients who actively participate by preparing beforehand for the visit, asking questions, and expressing concerns, get more information from their doctor, and in many cases receive more diagnostic and therapeutic action. second, patients can indeed be easily taught to use active communication behaviors during medical encounters. third, better communicators have better outcomes.a recent report of the institute of medicine (iom) noted that medication-related injuries are frequent, costly and in many cases preventable and strongly recommended that measures be instituted to strengthen patients' capacities for sound medication self-management and communication.

Eligibility criteria:
inclusion criteria: * 19 years of age or older * chronic nsaids (prescribed or recommended by their doctor) * seen by a primary care physician

Keywords: chronic nsaid use
determination of pneumothorax post lung biopsy

Conditions: Pneumothorax

Summary: bedside ultrasonography for detection of pneumothorax after transbronchial lung biopsies in lung transplant patients

the patients who undergo transbronchial forceps lung biopsies get a routine cxr after the biopsies are performed. the reason for cxr is to find out if pneumothorax occurred or not. cxr is required patient transportation and interpretation by the radiologist as well as time consuming. instead, we are planning to perform bedside ultrasound to determine if pneumothorax occurred or not

Eligibility criteria:
inclusion criteria: * any lung transplant patient who undergoes to bronchoscopic lung biopsy exclusion criteria: * patients develop respiratory failure during the procedure
feasibility of telehealth mindfulness for back pain in the emergency department

Conditions: Low Back Pain; Back Pain; Pain; Chronic Low-back Pain

Summary: while guideline-directed nonpharmacological strategies for chronic low back pain are well established, optimal chronic pain management for emergency department patients has yet to be defined. mindfulness interventions can be used for management of chronic conditions, yet are understudied as a primary approach for patients with chronic pain discharged from the emergency department. currently, there is limited evidence examining whether an individual telehealth mindfulness intervention is a feasible and acceptable for these patients. this study will develop, pilot, and evaluate the feasibility and effects of an 8-session (12-week) telehealth mindfulness intervention for patients with an acute exacerbation of chronic low back pain


Eligibility criteria:
inclusion criteria: 1. age 18 years or older; 2. presenting to the emergency department to address a chief complaint of an acute exacerbation of chronic low back pain; 3. meets nih-supported definition of chronic low back pain (e.g., pain greater than 3 months that has resulted in pain on at least half the days in the past 6 months); and 4. english-speaking due to feasibility of utilizing a telehealth mindfulness program developed in english exclusion criteria: 1. patients requiring hospitalization for a medical severe condition or comorbidity; 2. patients with a severe psychiatric or behavioral diagnosis or presenting symptoms, including psychosis, delirium, active suicidal ideation, or who screen positive on the columbia suicide screening; 3. patients with a history of multiple substance use or abuse; 4. patients involved in litigation related to the chronic pain condition; and 5. patients who are unable to comply with the telehealth intervention (i.e., unable to provide stable home address or access telehealth link on a mobile device or computer).

Keywords: mindfulness telehealth mindfulness-based intervention
hemodynamics in chronic kidney disease

Conditions: Chronic Kidney Failure

Summary: the goal of this observational study is to learn about the role of thoracic and whole body bioimpedance in the hemodynamic profile of patients with chronic kidney disease. the main question it aims to answer is: - is bioimpedance-determined fluid status associated with kidney function decline in patients with chronic kidney disease stage 3 - 5 (non dialysis).

participants will be measured during their regular visit to their treating nephrologist. during a follow up of one year, 3 or 4 visits will be scheduled. * bioimpedance and blood pressure measurements will be achieved by non-invasive techniques. * blood sampling will as much as possible coincide with regular blood samplings for clinical purposes. * all subjects will undergo echocardiography at baseline and after one year follow up.

Eligibility criteria:
inclusion criteria: * prevalent non-dialysis patients with estimated glomerular filtration rate \< 60 ml/min (for chronic kidney disease subjects) * age \> 18 years * signed informed consent exclusion criteria: * acute kidney injury * estimated glomerular filtration rate \< 20ml/min directly post-nephrectomy * clinical conditions affecting bioimpedance measurements: limb amputation, impaired skin integrity, brain stimulator, pacemaker with low threshold or unipolar pacemaker. * clinical conditions affecting body composition: liver cirrhosis, active infectious disease or any acute cardiovascular event (defined as cerebrovascular event, myocard infarction, heart failure) during the 3 months before screening for inclusion * pregnancy
effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: scale™ - diabetes

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this trial is conducted in africa, asia, europe and the united states of america (usa). the aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with type 2 diabetes. treatment will be added onto subject's pre-trial background diabetes treatment of either diet and exercise only or single compound oral antidiabetic drug (oad) treatment (metformin, sulphonylurea \[su\] or glitazone) or combination oad treatment (metformin, sulphonylurea or glitazone). the duration of the trial will be 56 weeks followed by a 12 week observational follow-up period.


Eligibility criteria:
inclusion criteria: * informed consent obtained * subjects diagnosed with type 2 diabetes and treated with either diet and exercise alone, metformin, sulphonylurea, glitazone as single agent therapy or a combination of the previously mentioned compounds * hba1c 7.0-10.0% (both inclusive) * body mass index (bmi) at least 27.0 kg/m\^2 * stable body weight * preceding failed dietary effort exclusion criteria: * treatment with glucagon-like peptide-1 (glp-1) receptor agonists, dipeptidyl peptidase-4 (dpp-4) inhibitors or insulin within the last 3 months * known proliferative retinopathy or maculopathy * history of acute or chronic pancreatitis * obesity induced by drug treatment * use of approved weight lowering pharmacotherapy * previous surgical treatment of obesity * history of major depressive disorder or suicide attempt * uncontrolled hypertension (systolic blood pressure above or equal to 160 mmhg and/or diastolic blood pressure above or equal to 100 mmhg) * screening calcitonin of 50 ng/l or above * familial or personal history of multiple endocrine neoplasia type 2 (men2) or familial medullary thyroid carcinoma (fmtc) * personal history of non-familial medullary thyroid carcinoma
stocking of a busy emergency department

Conditions: Emergencies

Summary: stocking of essential supplies in an emergency department (ed) is crucial in order to efficiently and effectively take care of patients. when equipment and supplies are not available to patient care providers, an imbalance in the delivery of care is created. the amount of time nurses spend away from the bedside obtaining supplies has only been superficially studied; however, one study proposed that the majority of nurses spend 5 to 20 percent or more of their time during a shift. this results in 30 minutes to two-and-a-half hours of a twelve hour shift being lost to retrieving supplies that are not available. cabinets and drawers have recently been eliminated in the rooms and stock is kept in "supply towers" that contain all the necessary supplies to adequately take care of patients with the exception of medications, or stationary supplies. towers are restocked every morning by a stocking technician by taking the towers to the stock room, resupplying them based on previously established par levels, and utilizing a standard chart that describes exactly what supply, and how many to stock within a specified area of the cart. during their shift, the stocking technician must also respond to pages concerning low stock levels. hypothesis: nurses spend a significant amount of time away from the patient bedside during their shift looking for supplies.

objectives: * determine the amount of time nurses spend outside of a patient room obtaining supplies to care for the patient. * determine what supplies are obtained when the room is left. * determine how many times per shift the nurse leaves to obtain the same item. * determine if utilizing a "supply tower" located in patient rooms decreases the amount of time nurses spend obtaining supplies outside of a patient room to care for patients. * determine if implementation of a full time stocking technician decreases the amount of time that nurses spend outside a patient's room obtaining stock. * conduct spot checks on carts to determine if par levels are over, under, or exactly as established.

Eligibility criteria:
inclusion criteria: * nurse is an employee of lvhhn, and is working at the cc site. * nurse is working a full shift (7a-7p, 7p-7a, 7a-3p, 3p-11p, 11p-7a). * the nurse being observed is working in pod 1, pod 2, pod 3, or pod 4 at the cc site. * the supply needed is related to a procedural task for patient care. exclusion criteria: * the nurse is working at lvh-m or lvh-17. * the nurse being observed is working in the express care area or trauma bay. * the supply being obtained is a supply that is not maintained in the cart (appendix 2). * the nurse is scheduled for a shift less than 8 hours.

Keywords: hospital supplies stocking of supplies
home versus ambulatory monitoring, diurnal blood pressure profile, detection of non-dippers

Conditions: Hypertension

Summary: this is a cross-sectional study, including adults, either untreated for hypertension, or under stable treatment for more than four weeks. assessment will include: clinic blood pressure measurements with an automated oscillometric device, 24-hour ambulatory blood pressure monitoring home blood pressure monitoring during morning, evening and nocturnal measurements with the same device.

eligible patients, as described in inclusion/exclusion criteria, will be instructed to use microlife watchbp home-nocturnal oscillometric device, in order to measure their bp two times with one-minute interval, in the morning between 6 and 9 am and in the evening between 6 and 9 pm respectively for six days. these six days shall be normal working days, selected be the patient, within a time-frame of two weeks approximately. patients should be sitting for at least five minutes and calm. during three out of those six days, they will apply and activate the same device, in order to take bp measurements while they will be asleep. those measurements are going to be taken automatically by the device, the first 2-hours after the activation and another two with one-hour interval. measurements will be averaged as awake and asleep bp values, with a potential to derive, if so wished, separate averages of awake-morning and awake-evening bp values. microlife watchbp o3 ambulatory blood pressure measurement (abpm) device will be applied by a doctor to each patient and it will be removed the next day by a doctor. bp measurements will be performed every 20 minutes for 24 hours. bp measurements taken during awake and asleep hours for each patient, will be analyzed separately. additionally, triplicate sitting clinic blood pressure measurements, with one-minute interval, will be performed with the microlife watchbp home-nocturnal device during each patient's visit at the hypertension center. patients will visit hypertension center three times, one to apply the abpm device and one to remove it and provide the microlife watchbp home-nocturnal device and another one to bring it back. this will take approximately two weeks.

Eligibility criteria:
inclusion criteria:ma * patients referred for high blood pressure * age over 30 years * untreated for hypertension or under stable treatment for 4 weeks or more * patients physically and mentally capable for self-measurement of blood pressure at home * written informed consent to participate in the study exclusion criteria: * sustained arrythmia * pregnancy * symptomatic cardiovascular disease * any other serious disease (renal failure, heart failure, malignancy)

Keywords: hypertension nocturnal bp dipping home blood pressure monitoring ambulatory blood pressure monitoring